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This NIH-funded multicenter randomized study of focal
segmental glomerulosclerosis (FSGS) treatment compared
the efficacy of a 12-month course of cyclosporine to a
combination of oral pulse dexamethasone and
mycophenolate mofetil in children and adults with steroid-
resistant primary FSGS. Of the 192 patients enrolled, 138
were randomized to cyclosporine (72) or to mycophenolate/
dexamethasone (66). The primary analysis compared the
levels of an ordinal variable measuring remission during the
first year. The odds ratio (0.59) for achieving at least a partial
remission with mycophenolate/dexamethasone compared to
cyclosporine was not significant. Partial or complete
remission was achieved in 22 mycophenolate/
dexamethasone- and 33 cyclosporine-treated patients at
12 months. The main secondary outcome, preservation of
remission for 26 weeks following cessation of treatment, was
not significantly different between these two therapies.
During the entire 78 weeks of study, 8 patients treated with
cyclosporine and 7 with mycophenolate/dexamethasone
died or developed kidney failure. Thus, our study did not
find a difference in rates of proteinuria remission following
12 months of cyclosporine compared to mycophenolate/
dexamethasone in patients with steroid-resistant FSGS.
However, the small sample size might have prevented
detection of a moderate treatment effect.
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Focal segmental glomerulosclerosis (FSGS) is one of the
leading causes of end-stage kidney disease (ESKD). The
5-year kidney survival rates approach 100% occur following
complete proteinuria remission, 90% after partial remission
and 60% with treatment resistance.1–5
The initial treatment of primary FSGS usually involves
corticosteroids3,6 and results in proteinuria remission in
B25% of patients.4,7,8 In observational and uncontrolled
trials, prolonged prednisone therapy (mean 9 months) in
adults resulted in complete and partial remission rates of 33%
and 29%, respectively.9 Smith et al.10 evaluated pulse oral
dexamethasone (DEX) over 32 weeks in 15 adults with
primary FSGS and nephrotic range proteinuria. One complete
remission and six partial remissions (urine protein/creatinine
(Up/c) o2 grams per grams (g/g)) were observed, yielding a
combined response of 47%, which fell to 20% with longer
follow-up. Uncontrolled data from a single center suggest
improved control of FSGS with long-term high-dose pulse
corticosteroid therapy in conjunction with cytotoxic agents
compared with historic controls.11 Together, these studies
suggest that long-term corticosteroid therapy may improve
the partial and complete remission rate in patients with FSGS
and resistance to a standard short course of corticosteroids.
The only medications that have been evaluated in
randomized clinical trials (RCTs) and have shown to increase
the rate of partial and complete remission are cyclosporine
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(CSA) coupled with low-dose prednisone.12,13 The high
relapse rate following discontinuation of CSA12 and its side-
effect profile, including nephrotoxicity, have stimulated a
search for alternative therapy. Mycophenolate mofetil
(MMF), which reduces proteinuria in steroid-resistant
FSGS with less toxicity than CSA,14,15 has not been tested
in a large RCT.
Thus, there is an urgent need to evaluate available and new
therapies for FSGS in a systematic manner. The National
Institutes of Health (NIH)-funded FSGS Clinical Trial (FSGS
CT) is a multicenter RCT that compared the efficacy of a
12-month course of CSA to a combination of oral pulse DEX
and MMF in children and adults with steroid-resistant
primary FSGS. This article presents the primary and main
secondary outcomes of this trial. A previous publication has
provided details about the study design and cohort.16
RESULTS
Patient disposition
A total of 192 patients were enrolled and 138 were
randomized. The most common reasons for exclusion of
the 54 enrolled but ineligible patients were lack of FSGS
lesion on kidney biopsy (N¼ 18), Up/c o1 (N¼ 20), and
estimated glomerular filtration rate (eGFR) o40 ml/min per
1.73 m2 (N¼ 5). Patient randomization, allocation and
follow-up are summarized in Figure 1. Over the study
period, 6 (4%) died or reached ESKD by week 26, 12 (9%)
died or reached ESKD by week 52, and cumulative 15 (11%)
died or reached ESKD before week 78. Missing visits from
patients who had not reached a primary outcome of
treatment failure, ESKD, or death occurred in 11 patients
(8%) at week 26, 2 (1%) at week 52, and 8 (6%) at week 78
visits. The two patients who missed all three outcome
assessment visits did not receive study drug following
randomization (one MMF/DEX and one CSA). One of these
patients developed diabetes between the screening and
randomization visit, which was detected immediately after
randomization. The other was lost to follow-up immediately
after randomization, but was observed to be in remission 13
months after the initial evaluation. Both patients were
assigned a level 6 (failure) primary outcome and were
included in the intent-to-treat primary outcome analysis.
Baseline characteristics
Baseline characteristics were balanced between the 72 patients
randomized to CSA and 66 randomized to MMF/DEX
(Table 1). The randomized cohort included 93 (67%)
children aged o18 years, 53 (38%) blacks, 73 (53%) males,
48 (35%) with baseline eGFR p90 ml/min per 1.73 m2,
33 (24%) and 36 (26%) with baseline Up/co2 g/g and 2–4 g/g,
respectively, and 77 (56%) with a serum albumin
p3.0 mg/dl.
Drug dosing
The mean time-averaged prescribed dose plus or minus s.d.
for the CSA arm was 4.6±1.7 (range 1.6–9.0) mg/kg/day and
for MMF was 26.2±6.1 (range 13.4–41.2) mg/kg/day.
Patients were treated with either angiotensin-converting
enzyme inhibitor lisinopril (85.5% (118/138)) or angiotensin
receptor blocker losartan (7.9% (11/138)), 4.3% (6/138) were
switched from lisinopril to losartan during the study, 1.4%
(2/138) did not receive any study drug, and 0.7%
(1/138) did not receive angiotensin-converting enzyme or
angiotensin receptor blocker because of allergies but was
Baseline 66 Randomizedto MMF/DEX
Wk 26
Wk 52
Wk 78
40 Wk 26
treatment failures
1 Death (Wk 0-Wk 26) 0 Deaths (Wk 0-Wk 26)
3 ESKD (Wk 0-Wk 26)
6 Missed Wk 26
33 Wk 26 failures
among 39 Wk 26 remissions:
0 Deaths (Wk 26-52)
0 ESKD (Wk 26-52)
2 Missed Wk 52*
0 Deaths (Wk 52-78)
0 ESKD (Wk 52-78)
7 Missed Wk 78
26 With Wk 78
39 Total failures by Wk 52
among 33 Wk 52 remissions:
63 With Wk 26
33 Wk 26
treatment failures
6 Additional Wk 52
treatment failures
40 Wk 26 failures
among 26 Wk 26 remissions:
0 Deaths (Wk 26-52)
138
Randomized
72 Randomized
to CSA
0 ESKD (Wk 26-52)
0 Missed Wk 52
26 With Wk 52
0 Deaths (Wk 52-78)
0 ESKD (Wk 52-78)
1 Missed Wk 78
21 With Wk 78
44 Total failures by Wk 52
among 22 Wk 52 remissions:
2 ESKD (Wk 0-Wk 26)
5 Missed Wk 26
58 With Wk 26
4 Additional Wk 52
treatment failures
Figure 1 | Summary of randomized subject disposition. Treatment failure was declared if a subject either met a final outcome status of
no remission (failure to achieve at least a partial remission by week (Wk) 26 (category 5 and 6) or failure to achieve a partial or complete
remission by week 52) or reached a protocol-defined study stop point. *2 missing week-52 visits were assigned treatment failure outcome
and are included in the 6 week-52 treatment failures. CSA, cyclosporine; DEX, dexamethasone; ESKD, end-stage kidney disease; MMF,
mycophenolate mofetil.
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treated with the main study interventions. Additional
antihypertensive therapies were not restricted by study
protocol. The time-averaged dose of lisinopril was
0.36±0.12 (range 0.04–0.56) mg/kg/day and of losartan was
1.10±0.50 mg/kg/day (range: 0.55–2.69).
Blood pressure. Systolic blood pressure (median (inter-
quartile range)) for adults in the MMF arm at baseline was
120 mm Hg (16), at week 26 was 120 mm Hg (16), at week 52
was 121mm Hg (17), and at week 78 was 121mm Hg (22).
Median systolic blood pressure in the CSA arm for adults at
baseline was 129 mm Hg (18), at week 26 was 124 mm Hg
(18), at week 52 was 125 mm Hg (22), and at week 78 was
118 mm Hg (21). In children, the median systolic blood
pressure in the MMF arm at baseline was 117 mm Hg (22), at
week 26 was 113 mm Hg (22), at week 52 was 110 mm Hg
(52), and at week 78 was 110 mm Hg (23). For children in the
CSA arm, the median (interquartile range) systolic blood
pressure at baseline was 115 mm Hg (19), at week 26 was
109 mm Hg (22), at week 52 was 111mm Hg (14), and at
week 78 was 114 mm Hg (19). The differences in blood
pressure between the CSA and MMF/DEX groups were not
statistically significant at any time point.
Primary and main secondary analyses
The distributions of the primary and main secondary
outcomes are displayed in Tables 2 and 3. As shown, 33
(46%) CSA patients and 22 (33%) MMF/DEX patients had a
primary outcome score of 1, 2, or 3, indicating achievement
of at least a partial remission at 1 year. Only 14 (19%) CSA
and 6 (9%) MMF/DEX patients had scores of 1 or 2,
indicating a complete remission. The primary analysis
comparing the mean level of the primary outcome between
the CSA and MMF/DEX groups was not statistically
significant (P¼ 0.11). The odds of at least a partial remission
at week 52 were lower for MMF/DEX than for CSA (odds
ratio (OR)¼ 0.59, 95% confidence interval (CI) 0.30–1.18)
but did not reach statistical significance. No randomized
patients were treated with the protocol-defined relapse
therapy during the week 0–52 study treatment period. During
the 78 week study period, 8 (14%) CSA and 7 (11%) MMF/
DEX subjects reached kidney failure or death (P¼ 0.56).
Main secondary outcome: sustainable remission
Of the 33 CSA patients who achieved at least a partial
remission at week 52, 11 (33%) relapsed after withdrawal of
immunosuppressive therapy, 16 (48%) retained at least a
partial remission, and 6 (18%) had an unknown week 78
remission status. Of the 22 MMF/DEX patients with a partial
or complete remission at week 52, 4 (18%) relapsed, 17
(77%) retained at least a partial remission, and 1 (5%) had an
unknown status at week 78 (P¼ 0.38). The OR comparing
MMF/DEX to CSA for maintaining at least a partial
remission at week 78 was 1.21 (95% CI 0.56–2.66). This
analysis excludes the seven patients assigned a main
secondary outcome level of 3.5 without Up/c measurements
after week 52; if these patients are included and assumed to
have sustained remissions, the OR becomes 0.85 (95% CI
0.41–1.78).
Subgroups
There were no significant differences in the treatment effects
between subgroups defined by patient age, race (black vs
non-black), baseline Up/c, baseline eGFR, or months of
previous steroid exposure (Figure 2). A trend for a beneficial
effect of CSA compared with MMF/DEX among patients
Table 1 | FSGS CT baseline characteristics comparing the
randomized treatment arms MMF/DEX and CSA
MMF/DEX (n=66) CSA (n=72)
Variable
N (%) or median
(IQR: Q1, Q3)
N (%) or median
(IQR: Q1, Q3)
Age (years)
2–12 20 (30.3%) 23 (31.9%)
13–17 25 (37.9%) 25 (34.7%)
18+ 21 (31.8%) 24 (33.3%)
Race
Black 26 (39.4%) 27 (37.5%)
White 38 (57.6%) 40 (55.6%)
Other 2 (3.0%) 5 (6.9%)
Hispanic 12 (18.2%) 14 (19.4%)
Male 33 (50.0%) 40 (55.6%)
Study baseline eGFR (ml/min
per 1.73m2)a
110.1 (80.6, 169.6) 112.8 (75.6, 194.2)
Up/c (g/g)
1–1.99 13 (19.7%) 20 (27.8%)
2–3.99 22 (33.3%) 14 (19.4%)
4–7.99 12 (18.2%) 19 (26.4%)
8+ 19 (28.8%) 19 (26.4%)
Albumin (g/dl) 2.7 (2.1, 3.7) 3.0 (2.3, 3.7)
Cholesterol, total (mg/dl)b 312 (260, 455) 283 (241, 390)
Hemoglobin 13.8 (12.9, 15.0) 14.0 (13.0, 15.2)
FSGS pathology subtype
NOS 43 (65.2%) 51 (70.8%)
Perihilar 4 (6.1%) 6 (8.3%)
Cellular 2 (3.0%) 2 (2.8%)
Tip 10 (15.2%) 4 (5.6%)
Collapsing 7 (10.6%) 9 (12.5%)
Duration of FSGS (months) 6.5 (3.2, 16.2) 7.1 (4.1, 16.3)
Previous steroid exposure
(months)c
3.0 (2.0, 6.0) 3.0 (2.0, 4.0)
Hypertension 39 (59.1%) 41 (56.9%)
Family history of kidney
diseased
6 (9.8%) 8 (11.6%)
BMI at screeninge 24.2 (20.4, 27.6) 23.0 (19.3, 29.9)
Abbreviations: BMI, body mass index; CSA, cyclosporine; DEX, dexamethasone;
eGFR, estimated glomerular filtration rate; FSGS CT, focal segmental glomerulo-
sclerosis Clinical Trial; IQR, interquartile range; MMF, mycophenolate mofetil;
NOS, not otherwise specified; Up/c (g/g), urine protein/creatinine grams per grams.
aThe study baseline is calculated using the average of serum creatinine measured at
screening and at the time of randomization.
bIn all, 65 CSA patients and 62 MMF/DEX patients had total cholesterol
measurement available at baseline.
cA total of 68 CSA patients and 59 MMF/DEX patients had data available on months
of previous steroid exposure at baseline.
dA total of 69 CSA patients and 61 MMF/DEX patients had data available on family
history of kidney disease at baseline.
eBMI is the measured BMI at screening. The obesity exclusion criterion for study
participation had to be met by BMI before first steroid exposure for nephrotic
syndrome.
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with baseline Up/c p4 g/g was present for the primary
outcome, but a similar trend was not observed for the main
secondary outcome. There was also no significant difference
in the treatment effect on the primary or main secondary
outcomes between those with a baseline Up/c o2 vs X2 g/g
(data not shown). There were 14 patients with a family
history of kidney disease: 8 in the CSA arm and 6 in the MMF
arm. Four of the CSA patients achieved at least partial
remission at week 52. Of them, two maintained the partial
remission at week 78, and one had a 3.5 as a secondary
outcome. All the six MMF patients with a positive family
history were treatment failures.
Other analyses of Up/c and eGFR
As shown in Figure 3, the median ratio (25th–75th
percentiles) of week 26 to baseline Up/c was smaller in the
CSA than the MMF/DEX group: CSA 0.24 (0.10–0.54) vs
MMF/DEX 0.46 (0.25–0.81) (P¼ 0.039). The smaller median
ratio indicates a larger decline of Up/c in the CSA group than
the MMF/DEX group. However, the median ratio of week 26
eGFR to baseline eGFR was also smaller in the CSA than the
MMF/DEX group, CSA 0.73 (0.63–0.89) vs MMF/DEX 0.95
(0.79–1.14) (P¼ 0.001), indicating a better preservation of
eGFR in the MMF/DEX-treated patients.
Adverse events
The summary of adverse events reported during the trial is
presented in Table 4. We report week 26 cumulative events, as
this is the time point where all participants have equal
opportunity to contribute an event. The number of adverse
events was similar in the two arms, and the observed
differences mainly reflect the known side-effect profile of the
test treatments.
Seven patients reached the 50% GFR decline and/or
dialysis stop point during the 78 week intervention phase. Six
patients, who reached the 50% decline in GFR point,
including 5 from the CSA arm at study weeks 0, 20, 38, 38,
and 52, subsequently progressed to end-stage renal disease
(ESRD). One meeting this criterion was in the MMF arm and
did not proceed to ESRD. One patient in the MMF arm
progressed to dialysis at week 32 after discontinuation of
prednisone (week 8), lisinopril (week 14), and MMF and
DEX (week 20; see below for details). One patient
experienced a pregnancy that was terminated.
Individual medications were discontinued within the
study intervention phase in 20 patients. MMF was
discontinued in one patient, mentioned above, who had
gastrointestinal toxicity (week 20) and who subsequently
progressed to ESRD (week 32). CSA was discontinued in
Table 2 | FSGS CT primary analysis comparing proteinuria remission by week 52 between the randomized treatment arms
Frequencies by primary
outcome level
Cumulative frequencies at
indicated level or better
Primary outcome level MMF/DEX CSA MMF/DEX CSA Odds ratio* 95% CI
1 2 (3.0%) 4 (5.6%) 2 (3.0%) 4 (5.6%) 0.53 (0.09–3.03)
2 4 (6.1%) 10 (13.9%) 6 (9.1%) 14 (19.4%) 0.41 (0.15–1.15)
3 16 (24.2%) 19 (26.4%) 22 (33.3%) 33 (45.8%) 0.59 (0.30–1.18)
4 4 (6.1%) 6 (8.3%) 26 (39.4%) 39 (54.2%) 0.55 (0.28–1.08)
5 15 (22.7%) 6 (8.3%) 41 (62.1%) 45 (62.5%) 0.98 (0.49–1.96)
6 25 (37.9%) 27 (37.5%) 66 (100%) 72 (100%) — —
Abbreviations: CI, confidence interval; CSA, cyclosporine; DEX, dexamethasone; FSGS CT, focal segmental glomerulosclerosis Clinical Trial; MMF, mycophenolate mofetil.
*P-value for primary analysis: 0.109. Odds ratios compare odds of achieving a primary outcome score equal to or better than the indicated level for MMF/DEX compared with
CSA. Odds ratioso1 indicate greater odds of better scores for CSA. The odds ratio of 0.59 for a primary outcome level ofX3 corresponds to a ratio in the probabilities of a
level of X3 of 0.73, 95% CI (0.48–1.11).
Table 3 | FSGS CT main secondary analysis comparing sustainable proteinuria remission from study weeks 52–78 between the
randomized treatment arms
Frequencies by main
secondary outcome level
Cumulative frequencies at
indicated level or better
Main secondary outcome level MMF/DEX CSA MMF/DEX CSA Odds ratio* 95% CI
1 3 (4.6%) 5 (6.9%) 3 (4.5%) 5 (6.9%) 0.64 (0.15–2.78)
2 1 (1.5%) 1 (1.4%) 4 (6.1%) 6 (8.3%) 0.71 (0.19–2.63)
3 13 (19.7%) 10 (13.9%) 17 (25.8%) 16 (22.2%) 1.21 (0.56–2.66)
3.5 1 (1.5%) 6 (8.3%) 18 (27.3%) 22 (30.6%) 0.85 (0.41–1.78)
4 4 (6.1%) 11 (15.3%) 22 (33.3%) 33 (45.8%) 0.59 (0.30–1.18)
5 44 (66.7%) 39 (54.2%) 66 (100%) 72 (100%) —
Abbreviations: CI, confidence interval; CSA, cyclosporine; DEX, dexamethasone; FSGS CT, focal segmental glomerulosclerosis Clinical Trial; MMF, mycophenolate mofetil.
*P-value for the main secondary analysis was 0.358. Odds ratios compare odds of achieving a main secondary outcome score equal to or better than the indicated level for
MMF/DEX compared with CSA. Odds ratios o1 indicate greater odds of better scores for CSA.
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four patients, including one with gout (week 14), one
with hirsutism (week 14), one with severe dyslipidemia
(week 14), and one patient choice (week 8). DEX was
discontinued in five patients. Three of these patients
discontinued at predefined stop points, according to
protocol, including one with MMF for gastrointestinal
toxicity (week 20, see above) and two because of hypergly-
cemia (weeks 2 and 2). Two others discontinued because of
fever (weeks 6 and 20), which subsequently resolved
but the drug was not restarted by physician/patient choice.
Of the two who discontinued for hyperglycemia, one
required insulin therapy and one progressed to ESRD at
month 24.
Prednisone was discontinued in six patients, two at the
predefined stop point of hyperglycemia (weeks 2 and 8), both
of whom were on the MMF/DEX arm. Of these two, one
required insulin therapy and one progressed to ESRD (week
32; see above). Additionally, two patients discontinued
prednisone because of cataracts (weeks 14 and 14), one with
severe dyslipidemia (week 14; see above), and one for anxiety
(week 20). Lisinopril/losartan therapy was discontinued in 10
patients, 7 of whom stopped at predefined stop points,
including 1 with angioedema (week 4), 1 with hypotension
(week 26), and 5 with declining GFR (weeks 14, 14, 20, 26,
and 65). In the latter group, one progressed to ESRD at week
32 and is counted above and two progressed to ESRD in
month 24. Three patients discontinued lisinopril/losartan
therapy for other indications, including two patients because
of patient choice (weeks 8 and 65) and one patient with
transient oliguria (week 0).
Subgroup analysis for primary and main secondary outcome
odds ratios and 95% confidence intervals
Primary outcome Main secondary outcome
0.0625 0.125 0.25 0.5 1.0 2.0 4.0 0.125 0.25 0.5 1.0 2.0 4.0 8.0 16.0
16.08.04.02.01.00.50.250.1254.02.01.00.50.250.1250.0625
Age < 18 (N=93)
Age  18 (N=45)
Race non-black (N=85)
Race black (N=53)
Baseline Up/c < 2 (N=33)
Baseline Up/c  2 (N=105)
Baseline eGFR  90 (N=47)
Baseline eGFR > 90 (N=91)
Previous steroid exposure  3 months (N=73)
Previous steroid exposure > 3 months (N=54)
Overall (N=138)
Figure 2 | Subgroup analyses for the primary outcome, proteinuria remission by 52 weeks, and main secondary outcome, sustained
remission between 52 and 78 weeks. Shown are odds ratios and 95% confidence limits comparing the odds of a primary outcome score
ofX3 (left) and of a main secondary outcome score ofX3 (right) between the MMF/DEX and CSA interventions for prespecified subgroups.
CSA, cyclosporine; DEX, dexamethasone; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; Up/c, urine protein/
creatinine.
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Figure 3 |Change in proteinuria and eGFR over time. (a) Ratio
of week 26:week 0 Up/c. Dark gray represents the CSA arm and
light gray represents the MMF/DEX arm. Shown are box plots
(indicating 5th, 25th, 50th, 75th, and 95th percentiles) of the ratio
of follow-up to baseline Up/c values. (b) Ratio of week 26:week 0
eGFR. Dark gray represents the CSA arm and light gray represents
the MMF/DEX arm. Shown are box plots (indicating 5th, 25th,
50th, 75th, and 95th percentiles) of the ratio of follow-up to
baseline eGFR values. CSA, cyclosporine; DEX, dexamethasone;
eGFR, estimated glomerular filtration rate; MMF, mycophenolate
mofetil; Up/c, urine protein/creatinine.
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Patients who reached a final outcome variable of
treatment failure at week 26 (level 6) were monitored every
6 months according to the protocol. At week 52, 8 of 37
(22%) week 26 MMF treatment failures and 8 of 30 (27%)
week 26 CSA treatment failures did not have week 52 urine
protein results documented. Of the week 26 treatment
failures completing the week 52 visit, 1 (3%) MMF failure
had complete remission at week 52, 3 (8%) of MMF and 2
(7%) of CSA failures had partial remission at week 52 (Up/c
between 0.2 and 2 g/g and reduction to o50% of baseline
value), and 2 (5%) of MMF and 4 (13%) of CSA arm reached
ESRD by week 52. One patient in the MMF arm died between
week 26 treatment failure and week 52. Between weeks 26 and
52, locally prescribed therapy for week 26 treatment failures
included: 2 calcineurin inhibitors, 5 MMF, 0 rituximab,
0 adalimumab, and 23 renin-angiotensin-aldosterone anta-
gonists. At week 52, the majority were off immunomodulating
therapies with 2 calcineurin inhibitors, 1 MMF, 0 rituximab,
0 adalimumab, and 6 remained on renin-angiotensin-aldo-
sterone antagonists.
DISCUSSION
This report describes the outcome of the largest RCT ever
performed in a cohort of pediatric and adult patients with
steroid-resistant primary FSGS. This sample represents a
well-characterized group of mainly incident patients follow-
ing initial corticosteroid therapy. Therefore, our findings
should be valid and generalizable to the population of
patients with newly recognized steroid-resistant primary
FSGS. The primary comparison between the CSA and MMF/
DEX groups failed to demonstrate a treatment difference in
remission rates between these interventions at 52 weeks. The
95% CI interval of 0.30–1.18 for the OR for achieving at least
a partial remission with MMF/DEX compared with CSA
Table 4 | Summary of adverse events comparing the randomized treatment arms
Weeks 0–26 Weeks 0–52
MMF/DEX (N=66) CSA (N=72) MMF/DEX (N=66) CSA (N=72)
Event
N pts with
events (N of
events
reported)
% of
pts
N pts with
events (N of
events
reported)
% of
pts
N pts with
events (N of
events
reported)
% of
pts
N pts with
events (N of
events
reported)
% of
pts
Serious infection requiring
hospitalizationa
7 (12) 10.6 5 (5) 6.9 9 (14) 13.6 7 (12) 9.7
Serious CVb 0 0.0 0 0.0 1 1.5 0 0.0
Hospitalizationa 14 (34) 21.2 12 (25) 16.7 18 (43) 27.3 17 (36) 23.6
Deathb 1 1.5 0 0.0 2 3.0 0 0.0
Gastrointestinalb 47 71.2 47 65.3 49 74.2 50 69.4
Coughb 49 74.2 43 59.7 53** 80.3 45** 62.5
Dermatologic conditionb 29 43.9 43 59.7 33 50.0 44 61.1
Hypotension/orthostasis/
dizzinessb
31 47.0 27 37.5 35 53.0 29 40.3
Infectiona 27 (65) 40.9 23 (43) 31.9 30 (81) 45.5 29 (70) 40.3
Painb 24 36.4 22 30.6 27 40.9 29 40.3
Neuropsych conditionb 16 24.2 22 30.6 16 24.2 23 31.9
Gingival hyperplasiab 0** 0.0 11** 15.3 0** 0.0 17** 23.6
Anemiab 10 15.2 11 15.3 11 16.7 16 22.2
Hypertensionb 6 9.1 11 15.3 7 10.6 12 16.7
Hyperlipidemiab 6 9.1 10 13.9 6 9.1 13 18.1
Hyperkalemiab 2 3.0 6 8.3 2 3.0 9 12.5
Non-serious CVb 6 9.1 4 5.6 7 10.6 4 5.6
Hyperglycemiab 6** 9.1 0** 0.0 6 9.1 2 2.8
Decreased muscle strengthb 5 7.6 3 4.2 5 7.6 3 4.2
Cataractb 3 4.6 0 0.0 4 6.1 1 1.4
Angioedemab 2 3.0 0 0.0 2 3.0 0 0.0
Thromboembolismc 1 1.5 1 1.4 1 1.5 1 1.4
Adrenal insufficiencyb 1 1.5 0 0.0 1 1.5 0 0.0
Alopeciab 1 1.5 0 0.0 1 1.5 0 0.0
Pregnancya 1 1.5 0 0.0 1 1.5 0 0.0
Abdominal crampsb 1 1.5 0 0.0 1 1.5 0 0.0
Decreased ANCa 0 (0) 0.0 0 (0) 0.0 1 (1) 1.5 0 0.0
Generalized tonic–clonic
seizurea
0 (0) 0.0 0 (0) 0.0 0 (0) 0.0 1 (4) 1.4
Abbreviations: ANC, absolute neutrophil count; CSA, cyclosporine; CV, cardiovascular; DEX, dexamethasone; MMF, mycophenolate mofetil; pts, patients.
aMultiple reports were recorded for these adverse events during the indicated time period of the study.
bOnly the first occurrence of these adverse events was recorded during the indicated time period of the study.
cIn one case the thrombus was intracardiac.
**Po0.02, Fisher’s exact test.
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extended over a wide range, and the lower limit of 0.30 leaves
open the possibility of a substantial benefit of CSA compared
with MMF/DEX that was undetected because of the trial’s
limited sample size. However, the proportions of patients
with complete or partial remission at week 52 were low in
both treatment arms—46% CSA and 33% MMF/DEX—
indicating that neither intervention consistently induced
remissions. Moreover, only a quarter of the patients in the
two groups had a sustained response 6 months following
discontinuation of immunosuppressive medications.
Although there were no significant treatment effects on
the primary or main secondary outcomes, which were
defined based on the occurrence and persistence of large
declines in proteinuria to designated thresholds, CSA was
significantly more effective than MMF/DEX in reducing
proteinuria, expressed as a continuous variable, over the first
26 weeks of therapy. However, the implications of this result
must be tempered by the deleterious impact of CSA on eGFR
and the proteinuria relapse rate subsequent to the disconti-
nuation of the either the CSA or MMF/DEX therapy. This
combined reduction in proteinuria and eGFR in response to
CSA tended to resolve after the study medications were
stopped. However, the findings raise questions about the
prognostic implications of short-term changes in proteinuria
and eGFR on clinically relevant outcomes like progression to
ESKD or death. A long-term observational study of the FSGS
cohort is planned to extend the follow-up period and answer
this important question.
Previous studies have evaluated calcineurin inhibitors in
FSGS and suggest benefit. In the largest published clinical
trial (n¼ 49), a 6-month course of CSA yielded a complete or
partial remission in 69% compared with placebo therapy
(4%) in adults with steroid-resistant FSGS. The relapse rate
was 8 of 18 (44%) within 6 months after discontinuation of
CSA treatment. A 50% decline in kidney function was
reported in B5% of CSA and 12% of the placebo arm at
study week 26 and kidney function continued to worsen in
the patients with more extended observation. The 4-year
renal survival rate was not statistically different (72% CSA vs
49% placebo, P¼ 0.1) but this interpretation may be subject
to type II error because of the small sample size.12
Our rate of remission in the MMF/DEX arm (33%) was
less than that reported by Tune and Mendoza (66%)17 and
Smith et al. (47%).10 This may reflect a national tendency to
treat patients with a longer course of corticosteroids before
defining steroid resistance and is reflected by the median
3-month cumulative exposure reported in patients at FSGS CT
study entry. MMF has been evaluated only in small patient
series that provide limited information for comparison.14,15
Our study has several implications for the treatment of
primary FSGS. Because high-dose DEX pulse treatment was
incorporated into the experimental arm, it is unlikely that
increasing the strength or duration of steroid therapy will be
effective in achieving a consistently high rate of complete or
partial remission. Although this study did not demonstrate a
beneficial effect, appropriate use of CSA may merit continued
evaluation, especially in light of recent evidence that this
group of drugs may be acting on podocytes in a nonimmune
manner.18 The variable responses in proteinuria that ranged
from a sustained complete remission to treatment resistance,
in relationship to changes in eGFR and progression to CKD,
highlight the need to develop biomarkers of early FSGS that
can be used to define prognosis, predict response to
treatment, and provide a basis for selection of therapeutic
regimens on an individual basis.
It is important to acknowledge the strengths of this trial.
First, the diagnosis was confirmed by central review of biopsy.
Nearly 10% of the patients who were considered to have
FSGS based on local interpretation of their biopsies were
excluded when the specimens were reviewed by the central
pathologist. In addition, the study cohort was diverse with
respect to age, race, and ethnicity that may allow application
of results to similarly constructed populations.
The trial also had several weaknesses. First, based on
information that was available at the time of study
development, subjects were not classified according to the
presence of genetic mutations. Genetic testing has been
conducted as ancillary studies and will be reported separately.
The study incorporated no assessment of adherence beyond
patient reporting and CSA levels. Enrollment into the trial
was significantly lower than projected, so that moderate but
clinically important treatment effects may have gone
undetected. The sample size shortfall may have resulted from
an overestimation of the number of cases anticipated at each
site, the stringent definition of primary FSGS, and conflict
between the requirements of the protocol and site investiga-
tors’ assessment of the risks and benefits of the test agents.
Because of the enrollment challenges, the study Up/c
eligibility criterion was decreased from 42 g/g to 41 g/g
early in the study, the enrollment window was increased, and
extensive efforts were made to improve patient access and
participation. The study was closed with agreement from the
NIH study sponsor and Data Safety Monitoring Board
following review of the revised power analysis.
In conclusion, this trial did not demonstrate a difference
in proteinuria remission among patients with steroid-
resistant primary FSGS who were treated with CSA or
MMF/DEX. However, because of the limited sample size, a
beneficial treatment would have needed to increase the
absolute remission rate by B20% to provide 80% power;
smaller effects may have gone undetected. While either
regimen might be selected for future use with a similar
success rate, the overall low rate of remission raises the
important question of whether immunologically targeted
treatment is an optimal approach for this patient population.
The results of this trial underscore the need to identify new
biomarkers to delineate prognosis, potentially indicate new
therapeutic targets, and allow better appraisal of response to
treatments. It is hoped that the network of sites and the
infrastructure that was created for the FSGS CT can be
sustained and applied to future studies of this disorder and
other glomerular diseases.
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MATERIALS AND METHODS
Trial design
The FSGS CT is a multicenter, prospective, open-label RCT that
compared two treatment regimens: CSA and MMF/DEX pulses. The
study design is presented in a previous publication.16 CSA was
designated as the control arm based on the results of previous
clinical trials.12,13 DEX in combination with MMF (MMF/DEX) was
considered the experimental therapy.10,14,15
Eligibility criteria
Pediatric and adult patients were eligible if they had primary FSGS
confirmed by central pathology review of stored kidney biopsy
material, age of proteinuria onset and current age between 2 and 40
years, eGFRX40 ml/min per 1.73 m2 assessed at a single study visit,
Up/c 41 g/g, and corticosteroid resistance defined as persistent
proteinuria following a minimum of 4 weeks of corticosteroid
therapy. Details of the inclusion and exclusion criteria are provided
in the Appendix and previous publication.16
Physical examination and laboratory assessments
Interval history, occurrence of adverse events, weight, and edema
status were assessed at each visit. Edema was classified as the highest
score of the following: 1¼ extremity, 2¼ facial, 3¼ ascites, or
4¼ anasarca. Blood pressure was measured in the sitting and
standing positions. Blood and urine assays were conducted in the
Spectra East Core Laboratory. DNA was obtained at baseline, and
urine, serum, and plasma were obtained at baseline and weeks 26,
52, and 78 for storage in the NIDDK (National Institute of Diabetes
and Digestive and Kidney Diseases) Biosample and Genetic
Repositories.
Urine protein monitoring
Two first morning urine samples were required at screening,
baseline, and week 26, 52, and 78 visits. If the two Up/c values
differed by450%, a third urine sample was collected and the results
included in the average baseline Up/c. A single urine specimen was
collected at every other study visit.
Estimation of GFR
Participant eGFR was estimated by the Schwartz formula for age
o18 years19 and by the Cockroft–Gault formula adjusted for body
surface area for age X18 years.20 The measured weight was used in
the Cockroft–Gault calculations as it was not possible to accurately
estimate dry weight in edematous patients.
Randomization
Randomization schedules using randomly permuted blocks of
random sizes were prepared by the Data Coordinating Center.
Study investigators were blinded to these schedules. Allocation to
the two treatment groups was designed to be equal and stratified by
Core Coordinating Center, baseline eGFR (o90 vsX90 ml/min per
1.73 m2), and participant race (black vs non-black).
Monitoring schedule
Eligibility was confirmed based upon the screening visit, and
laboratory and pathology data before randomization. Treatment was
initiated after the baseline visit (week 0) and subsequent visits
occurred at weeks 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52, 65, and 78.
Long-term monitoring visits were conducted at 6-month intervals
until study closeout.
CSA
A dose of 5 to 6 mg/kg per day (maximum initial dose 250 mg/day)
was divided into two doses. The CSA dose was adjusted based on
drug levels in order to achieve a 12-h trough concentration of
100–250 ng/ml. CSA dose adjustments were made in 30% decre-
ments for prespecified toxicities.16
MMF and DEX
Participants were treated with MMF, 25–36 mg/kg per day (max-
imum 2 g/day), divided into two daily doses and DEX, 0.9 mg/kg per
dose (maximum 40 mg), daily on two consecutive days at the start of
weeks 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 30, 34, 38,
42, 46, and 50 for a total of 46 doses. MMF and DEX dose
adjustments were made in 30% decrements for prespecified
toxicities.10,16
Common therapy in both treatment arms
All participants were treated with prednisone (prednisolone for
children taking liquid preparation): 0.3 mg/kg per dose (maximum
15 mg) every other day for the first 6 months of the treatment
period. Lisinopril was provided for 18 months to a target dose of
0.4 mg/kg (40 mg maximum) daily. Doses were initiated at 25% of
the target dose and increased every 2 weeks until the target dose was
reached. Losartan was provided for angiotensin-converting enzyme
inhibitor-intolerant subjects (50 mg maximum initial dose and
100 mg maximum full dose). All other treatments, including
management of edema and control of blood pressure to achieve
standard target readings in pediatric and adult patients, were left to
the discretion of the site investigator.
Optional relapse therapy
The protocol allowed for a maximum of 2 weeks of prednisone
therapy dose of 2 mg/kg/day (max 60 mg/day) to treat a relapse. This
relapse therapy was permitted up to 2 times during study weeks 0–52
and was optional.
Time-averaged dose
Drug exposure for CSA, MMF, and lisinopril was expressed as a
time-averaged dose calculated through the 52 week visit. For week
26 treatment failures, the time-averaged dose was calculated through
week 26 only.
Stop points
Study stop points included a 50% decline from baseline eGFR to
eGFR p75 ml/min per 1.73 m2, dialysis, pregnancy, or prespecified
severe medication-related toxicity. When a stop point was
confirmed, serum chemistries, CSA level, complete blood cell count,
lipids, and Up/c were obtained.
Primary and main secondary outcomes
The primary outcome was defined by a six-level categorical
assessment of proteinuria remission during the first 52 weeks after
randomization. The scores ranged from 1 (most favorable) to 6
(least favorable) (Figure 4a) and were assigned as follows. Level 6
was failure to achieve partial or complete remission between weeks 2
and 26; level 5 was assigned if a partial or complete remission was
achieved at least once between weeks 2 and 20, but not at week 26.
The primary outcome for patients with scores of 5 or 6 was fully
determined by the week 26 visit. If a partial or complete remission
was achieved at week 26, patients were assigned to a score of 4 if a
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partial or complete remission was not achieved at week 52; 3 if a
partial remission was achieved at week 52; 2 if a complete remission
was achieved at week 52 but Up/cX0.2 at least once between weeks
26 and 52; and 1 if Up/c o0.2 for all Up/c measurements between
weeks 26 and 52.
The main secondary outcome was defined by a five-level ordinal
categorical variable characterizing maintenance of remission be-
tween weeks 52 and 78 following withdrawal of immunosuppressive
therapy (Figure 4b). A 5 (the worst outcome) was assigned to
patients who failed to achieve a partial or complete remission at
week 52. A 4 was assigned if no better than a partial remission was
maintained at all visits between weeks 52 and 78, a 3 was assigned if
a partial remission was achieved at week 78, a 2 was assigned if a
complete remission was achieved at week 78 but Up/c was X0.2 at
least once between week 52 and Week 78, and a 1 was assigned if the
patient maintained a complete remission from weeks 52 to 78.
The multilevel ordinal categorical outcomes were used instead of
simpler dichotomous classifications for remission in order to
increase statistical power and to allow patients to switch to
alternative therapy if a remission was not achieved by week 26.
Furthermore, the definitions of the primary and main secondary end
points required large clinically significant declines in Up/c in order
for positive outcomes to be recorded, thus reducing the susceptibility
of these outcomes to minor hemodynamic changes in Up/c.
Additional secondary outcomes were quality of life, adverse
events, and preservation of kidney function. Clinical sites were not
blinded to the results of the central Up/c measurements for subjects
under their care. Study investigators were blinded to results of
interim analyses done for the Data and Safety Monitoring Board.
Treatment failure
Treatment failure was declared if a subject either met a final
outcome status of no remission (failure to achieve at least a partial
remission by week 26 (category 5 and 6) or failed to achieve a partial
or complete remission by week 52) or reached a protocol-defined
stop point. Following the confirmation of treatment failure status,
the study medications were discontinued and therapeutic decisions
were deferred to the local nephrologist. These patients continued
in the study for observation and monitoring until the close of
the study.
Statistical methods
In accordance with the intention-to-treat principle, all randomized
patients were assigned nonmissing scores for both the primary and
main secondary outcomes. This was accomplished by treating all
scheduled Up/c measurements as nonremissions for the definition
of the primary and main secondary outcomes if they occurred after
death, ESKD, a 50% declining eGFR stop point, or early withdrawal
from this study before week 26. Patients who were in remission at
week 26 and subsequently lost to follow-up were assigned a primary
outcome score between 1 and 4 using a last-value-carried-forward
procedure. Patients who achieved a remission at week 52 but failed
to provide Up/c measurement after week 52 were assigned a score of
3.5 for the main secondary outcome, which was treated as
intermediate between scores of 3 and 4.
For both the primary and main secondary outcomes, the mean
outcome score was compared between the CSA and MMF/DEX
groups within each of the four randomization strata defined by
baseline eGFR and race. The results of these comparisons were
pooled across the strata using weights proportional to the strata
sample sizes. Standard errors for hypothesis tests were obtained as
linear combinations of multinomially distributed proportions of
participants in the respective remission categories. An estimate of
the effect size for the primary outcome with 95% CI was obtained as
the Mantel–Haenszel OR for achievement of at least a partial
remission at 1 year (levels 1, 2, or 3 on the primary outcome)
between the CSA and MMF/DEX groups with stratification for the
four randomization strata. Similarly, the treatment effect on the
main secondary outcome was expressed as the Mantel–Haenszel
stratified OR for maintenance of at least a partial remission until
week 78 (levels 1, 2, or 3 on the main secondary outcome).
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Figure 4 | FSGS CT outcome based on longitudinal control of
proteinuria. (a) Ordinal classification of FSGS CT proteinuria
primary outcome. Category 1: patients who achieved a complete
remission by week 26 that was sustained to week 52; category
2: patients who achieved a partial remission at week 26 and then
a complete remission at week 52; category 3: patients who
achieved a partial remission by week 26 that was sustained to
week 52; category 4: patients who achieved a partial remission at
week 26 and then had recurrence of proteinuria before week 52;
category 5: patients who achieved a partial remission before week
26 and then had a recurrence of proteinuria before week 26;
category 6: patients who never had a Up/c reduction of 450%
and an absolute value below 2g/g. (b) Ordinal classification of
FSGS CT main secondary outcome: sustainable remission of
proteinuria. Participants with a primary outcome level 4 to 6 were
assigned level 5. If the primary outcome was level p3, the main
secondary outcome was assigned to levels 1, 2, 3, or 4 as follows:
Level 4 was assigned if the participant failed to maintain at least a
partial remission from week 52 through week 78. Participants who
maintained at least a partial remission from week 52 through
week 78 were assigned to level 3 if they had a partial remission
at week 78, to level 2 if they had a complete remission at
week 78 but had at least one Up/c between 0.2 and 2.0 between
weeks 52 and 78, and to level 1 if they maintained a complete
remission from week 52 through week 78. FSGS CT, focal
segmental glomerulosclerosis Clinical Trial; Up/c, urine
protein/creatinine.
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In secondary analyses, changes in log-transformed Up/c and
eGFR from baseline to each follow-up visit through the week 26
assessment were summarized using box plots and compared
between treatment groups using the Wilcoxon rank-sums test,
stratified by the four randomization strata. In this analysis, an
eGFR value of 10 ml/min was imputed for five patients who
reached ESKD.
Adverse events corresponding to defined classes were tabulated
first for weeks 0–26 and again for weeks 0–52. Depending on the
nature of the adverse event, either the proportions of randomized
patients with at least one event or the rate of events (expressed as
number of events per patient-year) counting multiple events per
patient were compared between the treatment groups. Fisher’s exact
test was used to assess the statistical significance of comparisons at the
patient level and overdispersed Poisson regression was used for
comparisons of event rates where multiple events were counted for
each patient. All hypothesis tests were performed using a two-sided
a¼ 0.05, without adjustment for multiple comparisons.
Power
The FSGS CT was originally designed to randomize 500 patients and
would have provided 80% power at a two-sided a-level of 5% to
detect an absolute increase in remission probability ranging from
10.8% (from 32.5 to 43.3%) to 11.5% (from 60 to 70.5%) under
these remission rate scenarios.16 A total of 138 were actually
randomized, providing 80% power at the a-level of 5% to detect an
absolute increase in the probably of remission ranging from 20.9 to
18.2%. One formal interim analysis was performed using an
O’Brien-Fleming stopping boundary at 52% of the final achieved
information time.
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